Patents by Inventor Jimmy Van Wiltenburg
Jimmy Van Wiltenburg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200399243Abstract: The present invention relates to compounds of formula (1): wherein Q is selected from O or S; R1 is a 5-membered nitrogen-containing heteroaryl group substituted with R6 and optionally further substituted; R2 is an alpha, alpha?-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3 to 7 membered saturated or unsaturated, optionally substituted cyclic group; R5 is independently an optionally substituted C1-C4 alkyl group; and R6 is any group comprising a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: March 1, 2019Publication date: December 24, 2020Inventors: David MILLER, Jimmy VAN WILTENBURG, Matthew COOPER
-
Publication number: 20200361895Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; and R2 is a cyclic group substituted at the ?-position with a monovalent heterocyclic group or a monovalent aromatic group, wherein a ring atom of the heterocyclic or aromatic group is directly attached to the ? ring atom of the cyclic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: August 15, 2018Publication date: November 19, 2020Applicant: Inflazome LimitedInventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jimmy VAN WILTENBURG, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON, Thomas ALANINE, Stuart ONIONS, Ian STRUTT
-
Publication number: 20200331850Abstract: The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S; L is a saturated or unsaturated, optionally substituted C1-C12 hydrocarbylene group optionally including one or more heteroatoms N, O or S; R1 is —NR3R4, —OR5, —(C?NR6)R7, —(CO)R8, —CN, —N3, a quaternary ammonium group or an optionally substituted heterocycle; R3, R4, R5, R6, R7 and R8 are each independently hydrogen or a saturated or unsaturated, optionally substituted C1-C10 hydrocarbyl group optionally including one or more heteroatoms N, O or S; wherein optionally L and R3, or L and R4, or R3 and R4, or L and R5, or L and R6, or L and R7, or R6 and R7, or L and R8 together with the atom(s) to which they are attached may form a 3- to 12-membered, saturated or unsaturated, optionally substituted cyclic group; and R2 is a cyclic group substituted at the a-position, wherein R2 may optionally be further substituted; provided that the atom of L which is attached to the sulfur atom of the sulfonylurea groupType: ApplicationFiled: August 15, 2018Publication date: October 22, 2020Applicant: Inflazome LimitedInventors: David MILLER, Angus MACLEOD, Jimmy VAN WILTENBURG, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON
-
Publication number: 20200291003Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: July 4, 2018Publication date: September 17, 2020Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jimmy VAN WILTENBURG, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON
-
Publication number: 20200270227Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: July 4, 2018Publication date: August 27, 2020Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jimmy VAN WILTENBURG, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON
-
Publication number: 20200216389Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted C1-C15 hydrocarbyl group, wherein the atom of R1 which is attached to the sulfur atom of the sulfonylurea group is not a ring atom of a cyclic group; and R2 is a cyclic group substituted at the ?-position, wherein R may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.Type: ApplicationFiled: August 15, 2018Publication date: July 9, 2020Applicant: Inflazome LimitedInventors: David MILLER, Angus MACLEOD, Jimmy VAN WILTENBURG, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON
-
Publication number: 20190194107Abstract: Described is a method of synthesizing 6-(5-ethoxyhept-1-yl)bicyclo[3.3.0] octan-3-one by reacting 3-(5-ethoxyhept-1-yl) cyclopentene with dichloroketene. The resulting reaction products are reacted with acetic acid and zinc to produce 4-(5-ethoxyhept-1-yl)bicyclo[3.2.0]heptan-6-one and 4-(5-ethoxyhept-1-yl)bicyclo [3.2.0]heptan-7-one, which are reacted with trimethylsulfonium iodide to produce 2-(5-ethoxyhept-1-spiro[bicyclo[3.2.0]heptane-6,2?-oxirane] and 4-(5-ethoxyhept-1-yl)spiro-[bicyclo-[3.2.0]heptane-6,2?-oxirane]. Lithium iodide is reacted with 2-(5-ethoxyhept-1-yl)spiro[bicyclo-[3.2.0]heptane-6,2?-oxirane] and 4-(5-ethoxyhept-1-yl)spiro-[bicyclo-[3.2.0]heptane-6,2?-oxirane] to produce 6-(5-ethoxyhept-1-yl)bicyclo[3.3.0]octan-3-one. A method of synthesizing 6-(5-methoxyhept-1-yl)bicyclo[3.3.0]octan-3-one is also described.Type: ApplicationFiled: December 10, 2018Publication date: June 27, 2019Inventors: Jimmy van Wiltenburg, Rene La Crois
-
Patent number: 10150724Abstract: Described is a method of synthesizing 6-(5-ethoxyhept-1-yl)bicyclo[3.3.0] octan-3-one by reacting 3-(5-ethoxyhept-1-yl) cyclopentene with dichloroketene. The resulting reaction products are reacted with acetic acid and zinc to produce 4-(5-ethoxyhept-1-yl)bicyclo[3.2.0]heptan-6-one and 4-(5-ethoxyhept-1-yl)bicyclo [3.2.0]heptan-7-one, which are reacted with trimethylsulfonium iodide to produce 2-(5-ethoxyhept-1-yl)spiro[bicyclo[3.2.0]heptane-6,2?-oxirane] and 4-(5-ethoxyhept-1-yl)spiro-[bicyclo-[3.2.0]heptane-6,2?-oxirane]. Lithium iodide is reacted with 2-(5-ethoxyhept-1-yl)spiro[bicyclo[3.2.0]heptane-6,2?-oxirane] and 4-(5-ethoxyhept-1-yl)spiro-[bicyclo-[ 3.2.0]heptane-6,2?-oxirane] to produce 6-(5-ethoxyhept-1-yl)bicyclo[3.3.0]octan-3-one. A method of synthesizing 6-(5-methoxyhept-1-yl)bicyclo[3.3.0]octan-3-one is also described.Type: GrantFiled: January 30, 2017Date of Patent: December 11, 2018Assignee: Grey Pacific Labs, LLCInventors: Jimmy van Wiltenburg, Rene La Crois
-
Publication number: 20170204040Abstract: Described is a method of synthesizing 6-(5-ethoxyhept-1-yl)bicyclo[3.3.0] octan-3-one by reacting 3-(5-ethoxyhept-1-yl) cyclopentane with dichloroketene. The resulting reaction products are reacted with acetic acid and zinc to produce 4-(5-ethoxyhept-1-yl)bicyclo[3.2.0]heptan-6-one and 4-(5-ethoxyhept-1-yl)bicyclo [3.2.0]heptan-7-one, which are reacted with trimethylsulfonium iodide to produce 2-(5-ethoxyhept-1-yl)spiro[bicyclo[3.2.0]heptane-6,2?-oxirane] and 4-(5-ethoxyhept-1-yl)spiro-[bicyclo-[3.2.0]heptane-6,2?-oxirane]. Lithium iodide is reacted with 2-(5-ethoxyhept-1-yl)spiro[bicyclo[3.2.0]heptane-6,2?-oxirane] and 4-(5-ethoxyhept-1-yl)spiro-[bicyclo-[ 3.2.0]heptane-6,2?-oxirane] to produce 6-(5-ethoxyhept-1-yl)bicyclo[3.3.0]octan-3-one. A method of synthesizing 6-(5-methoxyhept-1-yl)bicyclo[3.3.0]octan-3-one is also described.Type: ApplicationFiled: January 30, 2017Publication date: July 20, 2017Inventors: Jimmy van Wiltenburg, Rene La Crois, Chantal Burnison
-
Patent number: 8410314Abstract: Described is a method of synthesizing 6-(5-ethoxyhept-1-yl)bicyclo[3.3.0]octan-3-one by reacting 3-(5-ethoxyhept-1-yl)cyclopentene with dichloroketene. The resulting reaction products are reacted with acetic acid and zinc to produce 4-(5-ethoxyhept-1-yl)bicyclo[3.2.0]heptan-6-one and 4-(5-ethoxyhept-1-yl)bicyclo[3.2.0]heptan-7-one, which are reacted with trimethylsulfonium iodide to produce 2-(5-ethoxyhept-1-yl)spiro[bicyclo[3.2.0]heptane-6,2?-oxirane] and 4-(5-ethoxyhept-1-yl)spiro-[bicyclo-[3.2.0] heptane-6,2?-oxirane]. Lithium iodide is reacted with 2-(5-ethoxyhept-1-yl)spiro[bicyclo[3.2.0]heptane-6,2?-oxirane] and 4-(5-ethoxyhept-1-yl)spiro-[bicyclo-[3.2.0]heptane-6,2?-oxirane] to produce 6-(5-ethoxyhept-1-yl)bicyclo[3.3.0]octan-3-one. A method of synthesizing 6-(5-methoxyhept-1-yl)bicyclo[3.3.0]octan-3-one is also described.Type: GrantFiled: June 20, 2011Date of Patent: April 2, 2013Assignee: BCS Business Consulting Services PTE Ltd.Inventors: Jimmy Van Wiltenburg, Rene La Crois